GlassScriptPhysician profile
Benjamin Glenn Kidder
NPI 1114259975
$34,659.88
in general payments reported to CMS, 2019-2025
62 companies · $6,014 in 2025
The $6,014 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,904 · 2020: $4,003 · 2021: $4,131 · 2022: $4,634 · 2023: $5,150 · 2024: $3,826 · 2025: $6,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $37.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,951.23 |
| Education | $37.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $7,497.59 | 2019-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $3,409.17 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $2,828.03 | 2019-2025 | Nuplazid |
| Ucb, INC. | $1,545.33 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Amneal Pharmaceuticals LLC | $1,179.86 | 2019-2025 | Rytary, Crexont |
| Novartis Pharmaceuticals Corporation | $1,157.63 | 2019-2025 | |
| Amgen INC. | $1,141.82 | 2019-2025 | Uplizna |
| Teva Pharmaceuticals USA, INC. | $961.84 | 2019-2025 | Austedo Xr |
| Pfizer INC. | $956.74 | 2021-2025 | |
| Allergan, INC. | $822.76 | 2019-2022 | |
| Grifols USA, LLC | $788.48 | 2019-2025 | Gamunex-C |
| Acorda Therapeutics, INC | $784.15 | 2019-2024 | Inbrija |
| Csl Behring | $706.77 | 2019-2025 | Hizentra |
| Lundbeck LLC | $656.53 | 2019-2025 | Vyepti, Rexulti |
| Mdd US Operations, LLC | $576.60 | 2019-2025 | Apokyn, Xadago, Apokyn |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $553.79 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $547.22 | 2019-2022 | |
| Lilly USA, LLC | $494.32 | 2021-2025 | Kisunla, Amyvid, Emgality |
| Neurelis, INC. | $477.05 | 2020-2025 | Valtoco |
| Argenx US, INC. | $471.07 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $463.02 | 2021-2023 | Zeposia |
| Biogen, INC. | $441.03 | 2019-2025 | Leqembi, Tysabri, Vumerity |
| Genzyme Corporation | $418.21 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $412.43 | 2019-2025 | Dysport |
| Otsuka America Pharmaceutical, INC. | $397.18 | 2023-2025 | Rexulti, Nuedexta |
| Supernus Pharmaceuticals, INC. | $394.19 | 2019-2021 | |
| Ge Healthcare | $388.71 | 2019-2025 | |
| Horizon Therapeutics Plc | $385.76 | 2021-2023 | Uplizna |
| Kyowa Kirin, INC. | $347.69 | 2022-2025 | Nourianz |
| Emd Serono, INC. | $344.20 | 2019-2025 | Mavenclad |
| Genentech USA, INC. | $295.90 | 2022-2025 | Ocrevus, Ocrevus Zunovo |
| Sk Life Science, INC. | $294.64 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $291.12 | 2019-2025 | Ultomiris, Soliris |
| Takeda Pharmaceuticals U.S.A., INC. | $249.54 | 2023-2025 | Hyqvia, Gammagard |
| Merz Pharmaceuticals, LLC | $248.33 | 2022-2025 | Xeomin, Inbrija, Ampyra |
| Biohaven Pharmaceuticals, INC. | $237.90 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $218.01 | 2022 | |
| Janssen Biotech, INC. | $138.43 | 2025 | |
| Avanir Pharmaceuticals, INC. | $130.24 | 2019-2021 | |
| Medtronic USA, INC. | $117.50 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $100.04 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $92.72 | 2021 | |
| Adamas Pharmaceuticals, INC. | $92.59 | 2019-2021 | |
| Springworks Therapeutics, INC. | $87.09 | 2025 | Gomekli |
| Janssen Pharmaceuticals, INC | $55.82 | 2022 | |
| Jazz Pharmaceuticals INC. | $55.71 | 2019 | |
| Tg Therapeutics, INC. | $53.93 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $49.82 | 2020-2022 | |
| Medtronic, INC. | $42.07 | 2021 | |
| Boston Scientific Corporation | $40.31 | 2024 | |
| Piramal Critical Care | $32.10 | 2022-2023 | |
| Tanabe Pharma America, INC. | $31.03 | 2022 | |
| Merz North America, INC. | $22.14 | 2019 | |
| Ani Pharmaceuticals, INC. | $20.84 | 2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $18.83 | 2020 | |
| Averitas Pharma INC. | $16.03 | 2023 | Qutenza |
| Nevro Corp. | $15.10 | 2022 | |
| Axsome Therapeutics, INC. | $13.83 | 2025 | Symbravo |
| Sumitomo Pharma America, INC. | $13.14 | 2023 | Aptiom |
| Zyla Life Sciences, INC. | $12.43 | 2019 | |
| Insightec,INC | $11.94 | 2024 | Exablate |
| Assertio Therapeutics, INC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Kidder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.